标题：Ibrutinib in B-cell lymphoma: Single fighter might be enough?
作者：Xue C.; Wang X.; Zhang L.; Qu Q.; Zhang Q.; Jiang Y.
作者机构：[Xue, C] Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250021, China;[ Wang, X] Dep 更多
通讯作者地址：[Jiang, Y] Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, No.324, Jingwu Road, China;
来源：Cancer Cell International
关键词：B cell receptor (BCR) signaling pathway; B-cell lymphoma; Bruton's tyrosine kinase (BTK); Ibrutinib; Monotherapy
摘要：Background: In recent years, the B cell receptor (BCR) signaling pathway has become a "hot point"because it plays a critical role in B-cell proliferation and function. Bruton's tyrosine kinase (BTK) is overexpressed in many subtypes of B-cell lymphoma as a downstream kinase in the BCR signaling pathway. Ibrutinib, the first generation of BTK inhibitor, has shown excellent antitumor activity in both indolent and aggressive B-cell lymphoma. Main body: Ibrutinib monotherapy has been confirmed to be effective with a high response rate (RR) and well-tolerated in many B-cell lymphoma subgroups. To achieve much deeper and faster remission, combination strategies contained ibrutinib were conducted to evaluate their synergistic anti-tumor effect. Conclusions: For patients with indolent B-cell lymphoma, most of them respond well with ibrutinib monotherapy. Combination strategies contained ibrutinib might be a better choice to achieve deeper and faster remission in the treatment of aggressive subtypes of B-cell lymphoma. Further investigations on the long-term efficacy and safety of the ibrutinib will provide novel strategies for individualized treatment of B-cell lymphoma. © 2020 The Author(s).